CerMed International Inc.
CerMed International Expands its Management Team
CerMed International Inc. / Key word(s): Change of Personnel
CONTACT CerMed International Expands its Management Team Monterey, CA – CerMed International, Inc. (GMS) based in Monterey, CA has announced the expansion of its management team. 'We are very pleased to have closed on phase one of our funding round which allows us to expand our management team and move the CerMap program forward. All of these executives bring significant expertise and accomplishments to CerMed. They are providing the leadership within their respective disciplines to enable the company to achieve the significant goals that we set for ourselves' said Peter Gombrich, CEO and Chairman. Mr. Drew Hofmann, Sr. VP, Business Development has been promoted to Executive Vice President, Chief Operating Officer for the Company. Mr. Hofmann has over 20 years of senior 'C' level management experience in both early and later stage medical device and diagnostics companies. He obtained a BS degree in Industrial Engineering, and did graduate studies in International Marketing from the University of Baltimore. Mr. Michael Perez has joined the company as Chief Financial Officer. He is a proven financial executive with over 25 years at the senior management level. He has a demonstrated record of achievement in both public and private companies, ranging from the start-up phase to large established corporations. Mr. Perez has taken a prior company public and participated in several secondary offerings and venture funding rounds. He has strong investor relations skills having served as the investor contact at various times in his career. Mr. Perez has a B.S. degree in Accounting from San Jose State University and an MBA from University of Santa Clara. Matthew Gombrich, M.D., M.S. has joined the company as Vice President of Clinical Affairs. Dr. Gombrich has extensive experience in medical affairs development, clinical trial design and execution focused on advancing market adoption in the area of infectious disease and cervical cancer diagnostics. Dr. Gombrich comes to CerMed having served most recently as President of Viridis Diagnostics. Prior to Viridis Dr. Gombrich was Director of Clinical Research/Medical Director at Inverness Medical. During his tenure at Inverness Dr. Gombrich was responsible for advancing several products in the infectious disease portfolio by structuring phase IV clinical trials aimed at increasing product visibility, advancing clinical utility, and expanding the CLIA status to include the products use in the 'waived' clinical setting. Other responsibilities included liaison to the FDA for post-market research proposals, Key Opinion Leader recruitment, clinical education and sales force training in the infectious disease product offerings. Dr. Gombrich received both his M.D. and M.S. from Case Western Reserve University in Cleveland, Ohio. Mr. Steve Roon has joined the company as Vice President of Sales and Marketing. Mr. Roon has a broad background in sales and marketing management in the pharmaceutical, research, and clinical diagnostic markets. Mr. Roon has over 30 years of experience in the sales and marketing of medical devices and diagnostics. He was Vice President of Sales and Marketing at Biolog, Inc. a microbiology company focused on microbial identification and functional genomics. In addition to expanding the domestic revenues, he also reorganized their European distribution and established a joint venture in Shanghai which he oversaw as Vice Chairman. Before joining Biolog, Mr. Roon was Global Vice President of Sales at SenDx Medical, Inc. He joined this diagnostic startup prior to commercial launch and his sales team delivered strong international and domestic revenues before the company was sold to Radiometer Medical A/S. About CerMed International CerMed International, Inc. is an emerging global medical device company that develops products and systems that help improve the health of women worldwide. These lower cost products will aid in reducing the risk of female reproductive diseases. They will enable women's health initiatives to be brought to the underserved regions of the world and empower women to personally take steps to reduce the risk of HIV and other STD's.
For information: http://www.cermedint.com End of Corporate News 03.05.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
122705 03.05.2011 |